We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

MINDRAY In-Vitro Diagnostics

  Gold Mindray offers a range of chemistry and hematology analyzers, designed to meet the needs of smaller labs as a main in... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Chemiluminescence Anti‐Müllerian Hormone Assay Performance Characterized

By LabMedica International staff writers
Posted on 18 Mar 2021
Print article
Image: The Mindray CL-2000i Chemiluminescence Immunoassay System (Photo courtesy of Mindray Bio‐Medical Electronics).
Image: The Mindray CL-2000i Chemiluminescence Immunoassay System (Photo courtesy of Mindray Bio‐Medical Electronics).
Müllerian hormone (AMH), a dimeric glycoprotein hormone, is a member of the transforming growth factor‐β superfamily that plays a predominant role in male and female sexual differentiation.

In males, AMH, which is expressed by sustentacular cells in the testis, promotes regression of the Müllerian ducts and maintains normal development of the reproductive system. In females, AMH is specifically expressed by granulosa cells of the developing pre‐antral and antral follicles and can be measured in the serum.

Medical Laboratory Scientists at the Southern Medical University (Guangzhou, China) collected residual serum samples after routine analysis from 1,055 blood donors (150 healthy males, 779 healthy females, and 126 women with polycystic ovary syndrome [PCOS]) presenting to a local hospital from August 2015 to October 2016.

Serum levels of AMH were detected with the Mindray AMH chemiluminescence immunoassay (CLIA) kit (Mindray Bio‐Medical Electronics Co., Ltd., Shenzhen, China) and determined with a Mindray CL‐2000i analyzer and the Roche AMH electrochemiluminescence immunoassay (ECLIA) kit (Roche Diagnostics International AG, Rotkreuz, Switzerland) and determined with the Roche Cobas E602 analyzer. Intra‐assay and total imprecision, analytical sensitivity, linearity, and interference were compared between the Mindray and Roche assays using pools of human serum. Additionally, male and female reference intervals were established using serum specimens collected from otherwise healthy groups and patients with PCOS.

The scientists reported that the intra‐assay and total imprecision percent coefficients of variation for low and high AMH serum levels were 2.74%/ 3.01% and 5.41%/5.35% respectively. The limits of blank, detection, and quantitation were 0.007, 0.01, and 0.03 ng/mL, respectively. The assay displayed good linearity over the range of 0.01–23 ng/mL. The coefficient of determination (R2) of the Mindray versus Roche assays was 0.9713 with 411 samples with AMH concentrations ranging from 0.014 to 22.1 ng/mL. The slope and intercept of the regression equation were 0.9687 and 0.3419, respectively. There was no significant interference from triglycerides (up to 3,000 mg/dL), bilirubin (up to 50 mg/dL), hemoglobin (up to 500 mg/dL), or total protein (up to 10 g/dL). Reference intervals showed the expected decrease in serum AMH levels with age in healthy women and increased levels in women with PCOS.

The authors concluded that the Mindray chemiluminescence assay for AMH demonstrated good performance for all evaluated parameters, including precision, detection capability, and linearity. This assay can applied in the laboratory for rapid assessment of ovarian reserve assessment and PCOS diagnosis. The study was published on March 4, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Southern Medical University
Mindray Bio‐Medical Electronics Co., Ltd
Roche Diagnostics International


Gold Supplier
ADAMTS13 Activity Assay
HemosIL ACUSTAR ADAMTS13 Activity Assay
New
Gold Supplier
Microplate Washer
MW-12A
New
Silver Supplier
SARS-CoV-2 qRT-PCR IVD Reagent Kit
SARS-CoV-2 qRT-PCR Dx Kit (CE-IVD)
New
Silver Supplier
Dyspeptic Diagnostic Test
GastroPanel

Print article
BIOHIT  Healthcare OY

Channels

Industry

view channel
Image: Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device (Photo courtesy of Quidel Corporation)

Quidel Receives Amended FDA Emergency Use Authorization for New AI-Powered Sofia Q Rapid Antigen Test Device

Quidel Corporation (San Diego, CA, USA) has received an amended Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) allowing the company to market Sofia Q, its latest addition... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.